Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
NICE has recommended panobinostat (also known as Farydak and manufactured by Novartis) as a possible treatment for people with multiple myeloma if they have had at least two prior therapies (including bortezomib and an immunomodulatory agent).
Panobinostat is recommended only if it is provided with the discount agreed in the patient access scheme.
The decision follows public consultation on a preliminary decision not to recommend panobinostat, with the manufacturer responding to the consultation by submitting a revised economic analysis which allowed the committee to recommend the drug.
Panobinostat is a new type of oral anti-cancer treatment that works by disrupting a key mechanism which causes normal cells to turn cancerous.
According to Cancer Research UK, in 2012 there were just over 4,000 new cases of multiple myeloma in England.
Source: NICE
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.